Cutaneous Leishmaniasis (CL) is a chronic wound disease of predominantly young patients which produces disfiguring scars that can lead to social exclusion, especially of female patients. The skin lesions are initiated by the body’s immune reaction to parasites transmitted through sand-fly bites. This neglected tropical skin disease has been known for ages in the Middle East. The consequences of war have always ignited cutaneous leishmaniasis through bad hygiene and poverty. The CL disease is also known as “Boil of Aleppo” since the time of the crusades. After Afghanistan and Iraq, Syria has recently become the number one CL endemic disease in the Mediterranean North Africa (MENA) region.
In the year 2000, the non-profit organization (NPO), Waisenmedizin e.V. was founded by physicians and pharmacists to help poor patients with diseases that are neglected by industrial research and development (R&D).
On August 30th, 2017, the German Regulatory Drug and Medical Device Agency, BfArM, has granted a special approval to the wound healing device LeiProtect®, developed by our NPO, Waisenmedizin e.V., to treat CL wounds after its painless application as shown on our campaign photo. This allows us to produce 60 kg of LeiProtect® to treat approximately 6,000 patients during the upcoming leishmania season.
We have already pre-financed the good manufacturing production (GMP) of 10 kg of LeiProtect® worth 9,350 € for Leishmaniasis patients in Syria and Algeria. We need funds to fully utilize the special BfArM approval.
Our medical aid is an essential contribution to peace in previously war torn countries coming from Europe. Every two euros you can spare helps cure one poor leishmaniasis patient and allows Europe to implement her founding idea as a peace searching state community.
Fifteen years of medical aid towards neglected diseases in Afghanistan have given us a distinctive competence in this domain and has created a network of trustworthy partners on-site for medical help in leishmania endemic countries.